Menu

Author Sues Journal

The American Diabetes Association faces a lawsuit after journal editors express concern over several papers.

Feb 10, 2015
Kerry Grens

WIKIMEDIA, BILL BRADFORDA professor from the State University of Campinas in São Paolo, Brazil, has asked the U.S. courts to put a stop to actions by the journal Diabetes, which has issued expressions of concern over several of his papers. According to the lawsuit, obtained by the Boston Business Journal, Diabetes is looking into a number of papers by Mário Saad and may retract them.

“Most detrimental,” the complaint states, “the ADA [American Diabetes Association, which publishes Diabetes] stated that it will not consider, for publication in any ADA journal any submissions authored by any of the faculty of (Saad’s) University until the issues described in the expression of concern have been appropriately reviewed and addressed by the University.” 

Retraction Watch pointed out that last year Saad and colleagues pulled a 2009 paper published in Arquivos Brasileiros de Endocrinologia & Metabologia for plagiarism.

The recent expressions of concern regarding four papers in Diabetes were issued because of the possibility of manipulated or fabricated data. Saad’s institution conducted an investigation, which found, Saad told Retraction Watch, “only editing mistakes that can be corrected by erratum.” The Boston Business Journal reported that the American Diabetes Association has asked the university to re-open the investigation.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.